Bobinac A, van Exel NJA, Rutten FFH, Brouwer WBF (2013) Valuing QALY gains by applying a
societal perspective. Health Econ 22(10):1272–1281
Bobinac A, van Exel NJA, Rutten FFH, Brouwer WBF (2014) The value of a QALY: individual
willingness to pay for health gains under risk. Pharmacoeconomics 32:75–86
Brouwer WBF, Culyer AJ, van Exel NJA, Rutten FFH (2008) Welfarism vs. extra-welfarism.
J Health Econ 27:325–338
Burns L, Orsini L, L’Italien G (2013) Value-based assessment of pharmacodiagnostic testing from
early stage development to real-world use. Value Health 16:16–19
Byron SK, Crabb N, George E, Marlow M, Newland A (2014) The Health Technology Assessment
of companion diagnostics: experience of NICE. Clin Cancer Res 20(6):1469–1476
Claxton K, Longo R, Longworth L, McCabe C, Wailoo A (2009) The value of innovation. Report
by the Decision Support Unit.https://www.nice.org.uk/proxy/?sourceUrl¼http%3A%2F%
2Fwww.nice.org.uk%2Fmedia%2FED8%2F7A%2FNICESubmissionAppendix.pdf. Accessed
4 Apr 2014
Claxton K, Walker S, Palmer S, Sculpher M (2010) Appropriate perspectives for health care
decisions. CHE Research Paper 54, Centre for Health Economics, University of Yorkhttps://
http://www.york.ac.uk/media/che/documents/papers/researchpapers/rp54_appropriateperspectives
for_health_care_decisions.pdf. Accessed 5 Apr 2014
CVZ (College voor zorgverzekeringen) (2006) Dutch Guidelines for Pharmacoeconomic Research,
Updated Version, http://www.ispor.org/peguidelines/source/HTAGuidelinesNLupdated2006.pdf.
Accessed 13 Jan 2014
CVZ (2009)http://www.cvz.nl/binaries/live/cvzinternet/hst_content/en/documents/assessments/
asm1011-cost-effectiveness-principle.pdf. Accessed 19 Jan 2014
Dakin HA, Devlin NJ, Odeyemi IA (2006) “Yes”, “No” or “Yes, but”? Multinomial modelling of
NICE decision-making. Health Policy 77(3):352–367
Danzon P, Towse A (2002) The economics of gene therapy and of pharmacogenetics. Value
Health 5:5–13
Dedes KJ, Szucs TD, Imesch P et al (2007) Cost-effectiveness of trastuzumab in the adjuvant
treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann
Oncol 18(9):1493–1499
Devlin N, Parkin D (2004) Does NICE have a cost effectiveness threshold and what other factors
influence its decisions? A binary choice analysis. Health Econ 13:437–452
Drummond M (2012) Twenty years of using economic evaluations for reimbursement decisions
what have we achieved? CHE Research Paper. 1-16https://www.york.ac.uk/media/che/documents/
papers/researchpapers/CHERP75_Using_economic_evaluations_for_reimbursement_decisions.
pdf. Accessed 13 Jan 2014
Drummond MF, Stoddart GL, Torrance GW (1997) Methods for the economic evaluation of health
care programmes, 2nd edn. Oxford University Press, Oxford
European Science Foundation (2012) Personalised Medicine for the European Citizen – towards
more precise medicine for the diagnosis, treatment and prevention of disease (iPM).http://
http://www.esf.org/publications/medical-sciences.html. Accessed 4 Apr 2014
Faulkner E, Annemans L, Garrison L et al (2012) Personalized Medicine Development and
Reimbursement Working Group challenges in the development and reimbursement of person-
alized medicine—payer and manufacturer perspectives and implications for health economics
and outcomes research: a report of the ISPOR Personalized Medicine Special Interest Group.
Value Health 8:1162–1171
Ferrusi IL, Marshall AD, Kulin NA, Leighl NB, Phillips KA (2009) Looking back at 10 years of
trastuzumab therapy: what is the role of HER2 testing? A systematic review of health
economic analyses. Per Med Mar 6:193–215
Fisher ES, Bynum JP, Skinner JS (2009) Slowing the growth of health care costs — lessons from
regional variation. N Engl J Med 360:849–852
Fishman PA, Hornbrook MC (2009) Assigning resources to health care use for health services
research: options and consequences.Med Care 47(Suppl 1):S70–S75
Economic Evaluations of Personalized Health Technologies: An Overview of... 133